Despite the FDA approval of AAV-based gene therapy for DMD in 2024, challenges persist in achieving substantial clinical benefits. The therapy, delandistrogene moxeparvovec, has shown promise in slowing disease progression by delivering a synthetic micro-dystrophin transgene. However, other gene therapy developers face obstacles such as immune-mediated adverse events and early patient deaths, hindering progress in the field.
Read more from ajmc.com
